. sanofi dengue prevention vaccine Dengvaxia wins USFDA approval but patient population limited to patients ages 916 httpow.lyLZqG30oC898Â

. @sanofi #dengue prevention #vaccine Dengvaxia wins @US_FDA approval, but patient population limited to patients ages 9-16: http://ow.ly/LZqG30oC898 

17:55 EDT 2 May 2019 | Genetic Engineering News

. @sanofi #dengue prevention #vaccine Dengvaxia wins @US_FDA approval, but patient population limited to patients ages 9-16: http://ow.ly/LZqG30oC898 

More From BioPortfolio on ". @sanofi #dengue prevention #vaccine Dengvaxia wins @US_FDA approval, but patient population limited to patients ages 9-16: http://ow.ly/LZqG30oC898 "